Tidmarsh was appointed in late July to be the director of the Centre for Drug Evaluation and Research. He didn’t instantly reply to a request for remark from Bloomberg News.
In an interview with the New York Times, Tidmarsh mentioned he was positioned on depart after he raised issues over the legality of a programme to hurry up approval of some new medication, which he believed “injected politics into the drug review programme.”
The agency positioned Tidmarsh on administrative depart on Friday after the Office of the General Counsel and the Office of Inspector General have been notified of “serious concerns about his personal conduct,” an HHS spokesperson mentioned.
On Sunday morning, Tidmarsh resigned, efficient instantly, the spokesperson mentioned, noting that HHS Secretary Robert F. Kennedy Jr. “expects the highest ethical standards from all individuals serving under his leadership.”
The division’s issues have been associated to a September LinkedIn publish the place Tidmarsh criticised the FDA’s 2021 approval of voclosporin, which is marketed beneath the identify Lupkynis and is used to deal with lupus nephritis, in keeping with two individuals accustomed to the matter who weren’t authorised to talk publicly.
The publish — which Tidmarsh later deleted — prompted shares of the drug’s maker, Aurinia Pharmaceuticals Inc. to drop sharply after his remark.
Tidmarsh beforehand served as chief government officer of La Jolla Pharmaceutical Co., whose then-chairman now serves as chair of Aurinia. Tidmarsh left La Jolla in 2019 “to pursue other interests,” in keeping with an announcement on the time.
Read Also: Trump says there ‘could be’ US troops on the ground in Nigeria; West African nation rejects threats